HOWL Stock Analysis: Buy, Sell, or Hold?
HOWL - Werewolf Therapeutics, Inc. Common Stock
$0.35
0.01 (2.12%)
▲
5d:
-10.88%
30d:
-18.0%
90d:
-56.63%
WAIT
LOW Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When HOWL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HOWL is down 10.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HOWL is down 10.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: HOWL is currently trading at $0.35, which is considered oversold relative to its 30-day fair value range of $0.37 to $0.53.
Technical Outlook: Technically, HOWL is in a downtrend. The price is currently testing key support at $0.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+1038.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HOWL is in a downtrend. The price is currently testing key support at $0.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+1038.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.37 -
$0.53
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1038.6% below Wall St target ($4.00)
- WARNING: Recommendation downgraded due to -10.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.37 -
$0.53
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.36
Resistance Level
$0.50
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.35
Wall Street Target
$4.00
(+1038.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 20, 2026 1:01 AM ET
Data refreshes hourly during market hours. Next update: 2:01 AM
Data refreshes hourly during market hours. Next update: 2:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HOWL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
17
Sells
Net
INSIDERS SELLING
Recent Transactions
Luke Evnin
SELL
38782 shares
2026-01-16
Luke Evnin
SELL
37413 shares
2026-01-15
Luke Evnin
SELL
30616 shares
2026-01-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 60 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
